Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
her2-peptide vaccine
- Development stage
- Phase 1
- Lead developer
- Galena Biopharma
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics, Peptides
- Administration
- Intradermal
01
Overview
The HER2-peptide vaccine is a therapeutic vaccine designed to stimulate an immune response against cancer cells that express the Human Epidermal Growth Factor Receptor 2 (HER2) protein. The active peptide component, nelipepimut-S (also known as E75), is derived from the extracellular domain of the HER2 protein. It functions by stimulating CD8-positive cytotoxic T-lymphocytes (CTLs) to recognize and destroy HER2-expressing tumor cells. In clinical trials, this vaccine is often administered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), which acts as an adjuvant to enhance the immune response by promoting the proliferation, maturation, and migration of dendritic cells, thereby augmenting antigen presentation. This combination has been investigated for the prevention of recurrence in breast cancer patients, including those with HER2 low-expressing tumors and ductal carcinoma in situ (DCIS).
- Brand names
- NeuVax
- Other names
- HER2/neu peptideHER2 peptideHER-2 peptideHER 2 peptide
02
Targets
HLA-A (HLA class I histocompatibility antigen A alpha chain)
Beyond the preview
Go deeper on her2-peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on her2-peptide vaccine.